Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients☆
Section snippets
Background
Clinical remission in rheumatoid arthritis (RA) is an achievable goal for some patients, especially in light of the availability of many new therapeutic options like anti-tumor necrosis factor (anti-TNF), anti CTLA-4 and anti-interleukin (IL)-6 receptor blockers. Remission in RA has been previously defined in several ways using different measurement instruments [1], [2], [3]; however these instruments' definition of remission varied in terms of their stringency [4]. In 2011, the American
Population and definition of remission
This study used data from the Consortium of Rheumatology Researchers of North America (CORRONA) from 2001 to 2011, which has been previously described [13], [14]. RA patients satisfying the 1987 American College of Rheumatology diagnosis criteria [15] were enrolled from academic and community rheumatology practices. Data from both physicians and patients were prospectively collected at enrollment and follow-up clinical encounters occurring at approximately 3–4-month intervals; at each visit,
Results
There were 2351 RA patients in remission according to the ACR/EULAR Boolean criteria at the most recently recorded CORRONA visit and 25,879 were not in remission. Table 1 shows the characteristics of patients in CORRONA according to remission status. The overall prevalence for new-onset RA remission was low (8%). Patients in remission uncommonly had comorbidities such as COPD, diabetes, or heart failure. The majority of patients in remission had low pain scores (86% with pain ≤1 on 0–10 visual
Discussion
After applying the ACR/EULAR Boolean remission criteria to a national US cohort, the overall point prevalence of clinical remission was low (8% overall). Based upon the presence or absence of varying comorbidities and use of different RA treatments, the prevalence of remission in various subgroups of RA patients was at most 11%. The likelihood of future remission varied modestly by RA therapies, especially for prednisone where higher doses were associated with a lower likelihood of remission.
References (20)
The CORRONA database
Autoimmun Rev
(2006)- et al.
A simplified disease activity index for rheumatoid arthritis for use in clinical practice
Rheumatology (Oxford)
(2003) - et al.
Activity assessments in rheumatoid arthritis
Curr Opin Rheumatol
(2008) - et al.
Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?
Ann Rheum Dis
(2005) - et al.
Assessing remission in clinical practice
Rheumatology (Oxford)
(2007) - et al.
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
Ann Rheum Dis
(2011) - et al.
Impact of comorbidity on physical function in patients with rheumatoid arthritis
Ann Rheum Dis
(2010) - et al.
Impact of age and comorbidities on the criteria for remission and response in rheumatoid arthritis
Ann Rheum Dis
(2005) - et al.
Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria
Ann Rheum Dis
(2011) - et al.
Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study
Arthritis Res Ther
(2011)
Cited by (16)
Prognostic Factors for Sustained Remission in a “Real Life” Cohort of Rheumatoid Arthritis Patients
2020, Reumatologia ClinicaAnalgesics in rheumatic diseases – a necessary component of therapy aimed at improving the quality of life
2022, Sovremennaya RevmatologiyaDYNAMICS OF PATIENT REPORTED OUTCOMES DURING THE USE VARIOUS BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS FOR RHEUMATOID ARTHRITIS
2022, Nauchno-Prakticheskaya RevmatologiyaSystematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis
2021, Arthritis Care and ResearchTreatment Strategies for Patients with Immune-Mediated Inflammatory Diseases
2021, JAMA - Journal of the American Medical Association
- ☆
Supported by the Agency for Healthcare Research and Quality (R01HS018517) and the National Institutes of Health (AR053351). CORRONA has received general support in the last 2 years from Abbott, Amgen, Astra Zeneca, Genentech, Janssen (Centocor), Lilly and Pfizer. Dr. Greenberg is a shareholder in CORRONA and has received consulting fees from AstraZeneca, CORRONA, Novartis, Pfizer. Dr. Curtis receives support from the NIH (AR053351), the Agency for Healthcare Research and Quality (R01HS018517), and the Roche/Genentech, UCB, Janssen, CORRONA, Amgen.